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Abstract
Background: In Ethiopia, malaria is caused by both Plasmodium falciparum and Plasmodium vivax.
Drug resistance of P. falciparum to sulfadoxine-pyrimethamine (SP) and chloroquine (CQ) is
frequent and intense in some areas.
Methods: In 100 patients with uncomplicated malaria from Dilla, southern Ethiopia, P. falciparum
dhfr and dhps mutations as well as P. vivax dhfr polymorphisms associated with resistance to SP and
P. falciparum pfcrt and pfmdr1 mutations conferring CQ resistance were assessed.
Results: P. falciparum and P. vivax were observed in 69% and 31% of the patients, respectively. Pfdhfr
triple mutations and pfdhfr/pfdhps quintuple mutations occurred in 87% and 86% of P. falciparum
isolates, respectively. Pfcrt T76 was seen in all and pfmdr1 Y86 in 81% of P. falciparum. The P. vivax
dhfr core mutations N117 and R58 were present in 94% and 74%, respectively.
Conclusion: These data point to an extraordinarily high frequency of drug-resistance mutations
in both P. falciparum and P. vivax in southern Ethiopia, and strongly support that both SP and CQ
are inadequate drugs for this region.
Background
In Ethiopia, malaria is endemic in three quarters of the
national territory [1] with Plasmodium falciparum predom-
inating over Plasmodium vivax. Some 13–28% of deaths in
children under five years of age are attributed to falci-
parum malaria [2]. Recently, a considerable increase in
malaria morbidity has been noted in the south and south-
west of Ethiopia. Possible reasons include climatic
changes, drug resistance and migration (e.g. from Sudan).
Also, epidemic outbreaks are now observed in highland
areas [3].
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In 1998, intense resistance of P. falciparum to chloroquine
(CQ) necessitated a change to sulfadoxine-pyrimeth-
amine (SP) as first-line antimalarial drug in Ethiopia.
However, recent data show a high mean SP treatment fail-
ure rate of 72% in some areas [4]. Consequently, another
change to artemether-lumefantrine (AL) was suggested in
2004 [5]. Yet, availability of AL is limited and 85% of the
population are living in rural areas with restricted access
to health care giving rise to a high rate of presumptive
treatment with available drugs like CQ or SP [6].
CQ resistance is associated with a T76 mutation of the P.
falciparum chloroquine resistance transporter gene (pfcrt)
[7] while a multidrug resistance analogue (pfmdr1) Y86
variation may modulate its degree [8]. P. falciparum resist-
ance to SP is conferred by mutations of the dihydropter-
oate synthase (pfdhps) and dihydrofolate reductase
(pfdhfr) genes [9]. In East Africa, the pfdhfr/pfdhps quintu-
ple mutation (triple pfdhfr (N108-I51-R59) + pfdhps G437
+ E540) is predictive for SP treatment failure, whereas in
West Africa the pfdhps alleles currently do not seem to sub-
stantially improve the predictive value of the pfdhfr triple
mutation [10,11].
P. vivax has long been considered intrinsically resistant to
pyrimethamine [12]. Nevertheless, pvdhfr  mutations
N117 and R58 corresponding to P. falciparum dhfr muta-
tions 108 and 59, respectively, are linked with SP resist-
ance and seem to arise first under drug pressure [13,14]. A
T117 mutation is seen in highly mutated genes [14]. Both
double (N117-R58) and triple pvdhfr mutations (N117-
R58-L57) are associated with delayed parasite clearance
following SP treatment [13].
Here, frequencies of relevant mutations in pfcrt, pfmdr1,
pfdhfr, pfdhps, and pvdhfr among isolates from southern
Ethiopia are presented.
Methods
The study was conducted in Dilla (population, approxi-
mately 15,000) located in a region characterized by the
gentle slopes of the southern Ethiopian rift valley system
ranging between an altitude of 1,400 to 2,000 metres
above sea level. The mean annual temperature ranges
between 17°C and 22.4°C, and the mean annual rainfall
is between 1200 and 1800 mm occurring in two rainy sea-
sons from March to May and from July to December [15].
Both P. falciparum and  P. vivax are endemic with pro-
nounced seasonal peaks. Subjects were enrolled from Jan-
uary to March 2004, i.e. during high transmission at the
end of a delayed rainy season. The study protocol was
reviewed and approved by the Regional Government
Health Bureau, Southern Nations, Ethiopia, and by the
Ethical Committee, Charité-University Medicine, Berlin,
Germany, and informed consent was obtained from
patients or parents.
One hundred patients presenting for primary health care
with fever or a history of fever and microscopically con-
firmed uncomplicated malaria were recruited. Treatment
followed national guidelines [16]. Finger-prick blood
samples were collected and malaria parasites were
counted on Giemsa-stained thick blood films per 200
white blood cells (WBC). Parasite density was calculated
based on a putative mean of 8000 WBC/μL. Aliquots of 10
μL of capillary blood were spotted on Whatman 3 MM fil-
ter paper, and DNA was extracted by commercial kits
(QIAmp blood kit, Qiagen). Parasite species was con-
firmed by nested polymerase chain reaction (PCR) assays
[17]. Restriction fragment length polymorphisms of PCR-
generated amplicons were applied to characterize the
codons: P. falciparum dhfr 51, 59, 108, pfdhps 436, 437,
540, 581, 613, pfcrt 76, pfmdr1 86, and P. vivax dhfr 57, 58,
61, 117. Restriction enzymes and conditions are described
elsewhere [18-20,13,14]. Laboratory strains and DNA-
samples of known genotype were used as positive con-
trols. Mixed alleles (both wildtype and mutant alleles
present) were considered mutant.
Results
The median age of the 100 patients (57 female, 43 male)
was 17 years (range 8 months to 60 years). P. falciparum
mono-infection,  P. vivax mono-infection, and P. falci-
parum-P. vivax co-infection were seen in 66, 28, and 3
patients, respectively. In three samples, PCR yielded no
result and at re-examination of thick films, no parasites
were observed. The geometric mean parasite density of P.
falciparum and P. vivax positive specimens was 21,797/μL
(95% confidence interval, 7,600–48,000) and 5,280/μL
(95% confidence interval, 880–16,800), respectively.
The results of P. falciparum genotyping for drug resistance
mutations are summarized in Table 1. All isolates showed
the CQ resistance pfcrt T76 core mutation and four out of
five additionally pfmdr1 Y86. Likewise, all isolates exhib-
ited the pfdhfr core mutation N108 and no wildtype alleles
at all three loci examined. In particular, the pfdhfr triple
mutation was seen in almost 90% (Table 1). Both pfdhps
G437 and E540 occurred in 97% whereas codons 436,
581 and 613 were all wildtype. Only two isolates dis-
played wildtype alleles in all pfdhps codons. Quadruple
mutations were not detected but quintuple variants were
found in 86% of P. falciparum-infected patients. As for P.
vivax pvdhfr, a N117 mutation was present in 94% of the
isolates, 74% of these additionally showed R58. Muta-
tions at codons 57 and 61 were found in only one speci-
men each (Table 2).Malaria Journal 2006, 5:54 http://www.malariajournal.com/content/5/1/54
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Discussion
Ethiopia comprises regions of largely differing malaria
endemicity and transmission. Considering the substantial
burden of disease in this country, there is a remarkable
shortage on country-wide data on the efficacy of antima-
larial drugs. A failure rate of 88% within two weeks fol-
lowing CQ treatment was reported from central Ethiopia
already in 1999 [21]. A recent multi-site survey demon-
strated mean SP treatment failure rates of 36% and 72%
within two and four weeks of follow-up, respectively [22].
AL, in contrast, was reported to achieve adequate clinical
and parasitological response in 99% [22].
In line with reports on high clinical failure rates of CQ and
SP, the obtained data shows that in an area of seasonal
transmission in southern Ethiopia, P. falciparum muta-
tions conferring resistance to these drugs are abundant. In
particular,  pfcrt  T76 and the pfdhfr  triple mutation
occurred in 100% and almost 90%, respectively. Also, pfd-
hfr G437 and E540 considered to confer high grade SP
resistance in the presence of the pfdhfr triple mutant [10]
were seen in all but two P. falciparum isolates. In addition,
with the exception of pfmdr1, mixed alleles comprising
both wildtype and mutation, were absent. Although only
approximative evidence, this suggests a rather low multi-
plicity of infection according with the seasonal nature of
malaria transmission in the study area.
The prevalence of pfdhfr triple and pfdhfr/pfdhps quintuple
(86%) mutations found in this study is extraordinarily
high. In Malawi, roughly three out of four patients
infected with parasites exhibiting quintuple mutations
have been reported to suffer SP treatment failure [10]. So
far, the predictive value of these markers for SP treatment
failure has neither been established in Ethiopia nor in the
study area. Though this predictive value may show some
variation between different locations [10,11], however,
overall and considering respective studies in East Africa
[23,10] these findings match with the extremely poor SP
efficacy rates seen in this country [4]. In Jima, southern
Ethiopia and some 200 km West of Dilla, 54% of P. falci-
parum isolates have recently been reported to carry the pfd-
hfr/pfdhps  quintuple mutation [24] highlighting the
uneven distribution of drug resistance in the country. Fur-
thermore, the prevalence of quintuple mutants in the
present study exceeds respective numbers in other African
Table 2: Prevalence of Plasmodium vivax dihydrofolate reductase mutations associated with resistance to sulfadoxine-pyrimthamine in 
isolates from southern Ethiopia (n = 31)
Pvdhfr codon Wildtype (%) Mutation (%) Mixed (%)a
57 30 (97%) 1 (3%) 0
58 8 (26%) 21 (68%) 2 (6%)
61 30 (97%) 0 1 (3%)
117 2 (6%) 29 (94%) 0
a both wildtype and mutant allele were found
Table 1: Prevalence of mutations conferring resistance to chloroquine and sulfadoxine-pyrimthamine in Plasmodium falciparum isolates 
from southern Ethiopia (n = 69)
Gene locus Mutation (%) Mixed type (%)a
Pfcrt 76 69 (100%) 0 (%)
Pfmdr1 86 45 (65%) 11 (16%)
Dhfr 51 67 (97%) 0 (%)
Dhfr 108 69 (100%) 0 (%)
Dhfr 59 62 (90%) 0 (%)
Dhps 436 0 (0%) 0 (%)
Dhps 437 67 (97%) 0 (%)
Dhps 540 67 (97%) 0 (%)
Dhps 581 0 (0%) 0 (%)
Dhps 613 0 (0%) 0 (%)
Grouped dhfr/dhps alleles
Dhfr I51+N108 7 (10%) 0 (%)
Dhfr R59+N108 2 (3%) 0 (%)
Dhfr triple (I51+R59+N108) 60 (87%) 0 (%)
Dhfr/dhps quadruple (dhfr triple + dhps G437) 0 (0%) 0 (%)
Dhfr/dhps quintuple (quadruple + dhps E540) 59 (86%) 0 (%)
a both wildtype and mutant allele were foundMalaria Journal 2006, 5:54 http://www.malariajournal.com/content/5/1/54
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countries where SP had been used for a longer period of
time [23,25]. The reason for the abundance of mutations
conferring SP resistance in the study area of Dilla remains
obscure but the findings definitely supports usage of an
alternative first-line drug, e.g. AL.
Pfcrt T76, and to a lesser extent pfmdr1 Y86, are useful
markers of CQ resistance in areas where it is low to mod-
erate [20,26]. In the present study, the high prevalence of
pfcrt and pfmdr1 mutations match the known poor effi-
cacy of CQ in Ethiopia [21]. However, considering the
retraction of the drug at least from official first-line treat-
ment, perpetuation of resistant strains in the parasite pop-
ulation due to ongoing CQ usage also seems possible.
Unfortunately, pre-treatment drug levels could not be
assessed in the present study. Nevertheless, the obtained
results on CQ resistance markers may have importance for
subsequent monitoring: In areas where CQ was aban-
doned as first-line antimalarial, a recovery of CQ sensitiv-
ity and a decrease of pfcrt  mutations have been
demonstrated [27,28].
For P. vivax, high frequencies of pvdhfr N117 (94%) and
N117-R58 (74%) variations but no T117, triple or quad-
ruple mutations were observed. Although these multiple
mutations seem to be necessary for in vivo resistance
[13,14], this finding suggests widespread SP use since the
former arise first under drug pressure [13,14]. Higher fre-
quencies of pvdhr mutations are only found in Thailand
where double and triple mutations were detected in 99%
of isolates [13]. P. vivax substantially contributes to mor-
bidity in Ethiopia and differentiating P. falciparum from P.
vivax frequently is hampered by limited or absent micro-
scopic facilities. As this implies SP treatment of P. vivax
malaria, monitoring the resistance patterns seems worth-
while.
Conclusion
In conclusion, P. falciparum mutations conferring resist-
ance to CQ and SP are abundant in southern Ethiopia as
are mutations in P. vivax associated with SP resistance.
These findings strongly support the withdrawal of CQ and
SP and the introduction of AL as first-line drug for the
treatment of falciparum malaria. Repeated surveillance of
the parasites' molecular markers will enable to monitor
the development of resistance to CQ and SP in the region.
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